赛升药业(300485) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥132,698,154.36, a decrease of 30.92% compared to ¥192,096,898.81 in the same period last year[5] - Net profit attributable to shareholders was ¥823,935.60, down 99.23% from ¥106,545,165.76 year-on-year[5] - The total profit for Q1 2023 was ¥2,438,151.69, down 97.98% from ¥120,959,902.72 in the same period last year[8] - The net profit from continuing operations decreased by 99.62% to 406,467.27, primarily due to a reduction in fair value changes, decreased product sales, and increased R&D expenses[10] - The net profit attributable to the parent company fell by 99.23% to 823,935.60, mainly caused by decreased fair value changes and product sales[10] - The company's total equity as of March 31, 2023, was CNY 3,411,929,373.28, compared to CNY 3,411,987,428.00 at the beginning of the year, showing a slight decrease[22] - The net profit for the current period is 406,467.27, compared to 105,816,185.98 in the previous period, indicating a significant decrease[26] - The total profit for the current period is 2,438,151.69, down from 120,959,902.72 in the previous period[26] - Operating profit for the current period is 2,413,482.04, compared to 120,955,383.01 in the previous period, showing a substantial decline[26] Cash Flow - The net cash flow from operating activities was ¥4,769,162.32, a decline of 72.86% from ¥17,571,413.06 in the previous year[5] - Cash flow from operating activities showed a net decrease of 72.86% to 4,769,162.32, primarily due to lower sales revenue[10] - Cash inflow from operating activities totaled 153,241,637.71, compared to 216,783,818.26 in the previous period[30] - Cash outflow from operating activities amounted to 148,472,475.39, compared to 199,212,405.20 in the previous period[31] - The cash flow from investing activities showed a net decrease of 150.31% to -25,465,487.62, primarily due to increased turnover of financial investment principal[10] - The cash flow from investing activities resulted in a net outflow of -25,465,487.62, compared to a net inflow of 50,617,220.12 in the previous period[31] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥3,548,632,565.77, a slight decrease of 0.57% from ¥3,569,082,790.89 at the end of the previous year[5] - Total liabilities decreased to CNY 136,703,192.49 from CNY 157,095,362.89, representing a reduction of approximately 13.0%[22] - Cash and cash equivalents at the end of Q1 2023 amounted to CNY 205,198,355.58, down from CNY 226,210,562.87 at the beginning of the year, reflecting a decrease of approximately 9.0%[18] - Cash and cash equivalents at the end of the period decreased by 130.86% to -21,012,207.29, mainly due to uncollected short-term financial investments[10] Earnings Per Share - Basic and diluted earnings per share were both ¥0.0017, a decrease of 99.23% compared to ¥0.2212 in the same period last year[5] - Basic earnings per share dropped by 99.23% to 0.00, reflecting the decrease in profit[10] Research and Development - Research and development expenses increased by 59.10% to ¥26,803,792.38 from ¥16,846,915.01 in the same period last year[8] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 35,634[12] - The largest shareholder holds 49.51% of the shares, amounting to 238,464,000 shares[12] Other Income - The company reported a significant decrease in investment income, which fell by 96.73% to ¥674,100.99 from ¥20,627,695.57 year-on-year[8] - The company experienced a 98.74% reduction in other income, totaling ¥75,239.83 compared to ¥5,954,099.23 in the previous year[8] - The total comprehensive income decreased by 100.05% to -58,054.72, attributed to reduced fair value changes and increased R&D expenses[10] - Other comprehensive income after tax for the current period is -464,521.99, compared to -137,368.25 in the previous period[28] Inventory - Inventory increased to CNY 97,456,343.78 at the end of Q1 2023, compared to CNY 89,092,152.50 at the beginning of the year, marking an increase of about 9.5%[20] Corporate Actions - The company transferred its 45% stake in Zhongrun Weiye for CNY 6.6464 million during the reporting period, and no longer holds any equity in Zhongrun Weiye[16] - The subsidiary, Sai'er Biotechnology, was recognized as a high-tech enterprise, allowing it to benefit from a reduced corporate income tax rate of 15% for three years starting from 2022[16]